Bruker CORP 8-K filings

Bruker Corporation has completed its acquisition of ELITechGroup for $870 million in cash, excluding the clinical chemistry business, marking a significant expansion in molecular diagnostics.

Bruker Corporation has agreed to acquire substantially all assets of NanoString Technologies for approximately $392.6 million in cash, expanding its spatial biology portfolio.

Bruker Corporation has entered into three term loan agreements totaling CHF 450 million to support general corporate purposes, including potential acquisitions and debt refinancing.

Bruker Corporation announced a 20.6% year-over-year revenue increase for Q4 2023 and a 17.1% increase for the full year, driven by strong organic growth and strategic acquisitions.

Bruker Corporation has entered into a note purchase agreement to issue CHF 100 million in senior notes, split into two series, to institutional investors.

Bruker Corporation has entered into a note purchase agreement to issue CHF 331 million in senior notes to institutional investors, with the closing expected around April 15, 2024.

Bruker Corporation has entered into an amended and restated credit agreement, increasing its borrowing capacity to $900 million and extending the maturity date to January 18, 2029.